TD Cowen analyst Daniel Brennan maintained a Buy rating on GeneDx Holdings (WGS – Research Report) today and set a price target of $118.00. The ...

In 2022, before changing its name from Sema4 to GeneDx, the company had a dispute with UnitedHealthcare, which resulted in a ...

Wells Fargo notes that shares of GeneDx (WGS) are trading lower after a short report was published this morning by Grizzly Research, adding ...

Learn more about whether Clover Health Investments, Corp. or GeneDx Holdings Corp. is a better investment based on AAII's A+ ...

GeneDx (NASDAQ:WGS) shares maintained their ground following a reiteration of a Hold rating and a $75.00 price target by Jefferies analysts. According to InvestingPro data, analyst targets for the ...

Adds analyst comment. GeneDX (NASDAQ:WGS) fell 4% after a short report from Grizzly Research on the genetic testing company. Grizzly Research disclosed that it's short shares of GeneDX (NASDAQ:WGS).

Learn more about whether The Ensign Group, Inc. or GeneDx Holdings Corp. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

PFG Investments LLC bought a new position in GeneDx Holdings Corp. (NASDAQ:WGS – Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 3,274 shares of ...

GeneDx Holdings Corp. (NASDAQ:WGSWW – Get Free Report) was the target of a large drop in short interest in January. As of January 15th, there was short interest totalling 7,800 shares ...

GAITHERSBURG, Md., January 28, 2025--GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025 STAMFORD, Conn., January 17, 2025--GeneDx Holdings Corp ...

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and ...

Pre-Market: 9:04:59 a.m. EST ...